# OnCo record hla-a (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/hla-a/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "hla-a" ;
  schema:name "HLA-A"@en ;
  schema:alternateName "HLA-A*02"@en, "HLA-A*02:01"@en, "major histocompatibility complex, class I, A"@en, "HLA-A" ;
  schema:description "HLA-A is the molecule that holds up short pieces of a cell's proteins for T cells to inspect. Engineered T-cell receptor therapies such as tebentafusp and afami-cel only work in people with the HLA-A*02 variant, because the receptor recognises the tumour peptide sitting in that particular groove."@en ;
  schema:url <https://onco.cc/targets/hla-a/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4931>, <https://www.uniprot.org/uniprotkb/P04439/entry>, <https://www.ncbi.nlm.nih.gov/gene/3105> ;
  onco:tag "wave5-target" ;
  onco:targetClass "surface-antigen" ;
  schema:sameAs <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4931>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000206503>, <https://www.uniprot.org/uniprotkb/P04439/entry>, <https://www.ncbi.nlm.nih.gov/gene/3105> ;
  onco:related <https://onco.cc/targets/gp100/>, <https://onco.cc/targets/mage-a4/>, <https://onco.cc/targets/prame/>, <https://onco.cc/targets/cd3/> ;
  onco:cancers <https://onco.cc/cancers/uveal-melanoma/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/synovial-sarcoma/>, <https://onco.cc/cancers/sarcoma/> ;
  onco:technologies <https://onco.cc/technologies/tcr-t/> ;
  onco:drugs <https://onco.cc/drugs/tebentafusp/>, <https://onco.cc/drugs/afamitresgene-autoleucel/>, <https://onco.cc/drugs/letetresgene-autoleucel/>, <https://onco.cc/drugs/brenetafusp/> ;
  onco:pathways <https://onco.cc/pathways/antigen-presentation-immunoediting/>, <https://onco.cc/pathways/cancer-immunity-cycle/> .